LOS ALTOS, Calif., April 24, 2025 /CNW/ -- XYRA LLC, a private biopharmaceutical company, is committed to developing innovative therapies for cardiac rhythm disorders with high unmet need. With widespread use of FDA approved wearable Atrial Fibrillation (AF) monitoring devices in detecting as well as monitoring arrhythmias, it is now possible to identify subjects with long episodes of AF (LEAF) and symptoms who are at high risk of complications including stroke, heart failure and progression to permanent AF.
Read more at newswire.caThis article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.